ADVFN US – Market Content Editor
-
Sarepta shares drop after EU regulators reject Elevidys gene therapy
Shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) plunged 13% on Friday after a major regulatory blow in Europe. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on Elevidys, the company’s gene therapy designed to treat Duchenne muscular dystrophy. The CHMP declined to support approval of Elevidys for ambulatory…
-
Booz Allen Hamilton shares rally 4% as Q1 earnings top forecasts
Booz Allen Hamilton Holding Corporation (NYSE:BAH) saw its stock jump 4.24% in pre-market trading Friday after delivering fiscal Q1 2026 results that beat Wall Street expectations, even as revenue slipped slightly year-over-year. The McLean, Virginia-based technology and consulting firm posted adjusted earnings per share of $1.48 for the quarter ended June 30, exceeding analyst estimates…
-
Gorman-Rupp shares climb 3% on record Q2 earnings beat
Gorman-Rupp Company (NYSE:GRC) saw its stock rise more than 3% in pre-market trading Friday after reporting record-breaking second-quarter results that outpaced analyst expectations, fueled by infrastructure-related demand and solid municipal sales. The pump manufacturer reported earnings of $0.60 per share for the quarter, topping the average analyst forecast of $0.57. Revenue hit an all-time high…
-
GrafTech slides over 2% as Q2 earnings come in below expectations
GrafTech International Ltd. (NYSE:EAF) saw its shares drop 2.22% in pre-market trading Friday after reporting second-quarter results that fell short of analyst forecasts, despite delivering its strongest sales volume since Q3 2022. The graphite electrode maker posted an adjusted loss of $0.16 per share, underperforming Wall Street’s estimate of a $0.13 loss. Revenue for the…
-
OneMain Holdings surpasses Q2 forecasts as credit indicators strengthen
On Friday, OneMain Holdings, Inc. (NYSE:OMF) announced second-quarter adjusted earnings that outpaced analyst predictions, supported by enhanced credit metrics and robust loan growth. Following the announcement, the company’s shares climbed 1.48% in pre-market trading. The consumer finance provider reported adjusted earnings per share of $1.45 for the quarter, well above the analyst consensus of $1.23.…
-
Lear Shares Drop Nearly 10% After Q2 Earnings Miss Despite Revenue Beat
Lear Corporation (NYSE:LEA), a leading name in automotive technology, reported second-quarter earnings that fell short of analyst expectations on Friday, even though revenue slightly surpassed forecasts. Following the earnings release, Lear’s stock plunged 9.83% in pre-market trading. The company posted earnings per share of $3.06 for Q2, missing the analyst consensus of $3.26 by 20…
-
Eli Lilly’s Alzheimer’s Drug Kisunla Receives Positive CHMP Recommendation
Eli Lilly (NYSE:LLY) announced that its Alzheimer’s medication Kisunla (donanemab) has secured a favorable opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). The committee recommended Kisunla for treating early symptomatic Alzheimer’s disease. Following the CHMP’s endorsement, the European Commission is expected to issue a final regulatory decision on donanemab…
-
Portland General Electric Surpasses Q2 Estimates on Rising Data Center Demand
On Friday, Portland General Electric Company (NYSE:POR) announced second-quarter adjusted earnings of $0.66 per share, beating analyst forecasts of $0.64. This strong result was driven by a 16.5% quarter-over-quarter surge in demand, largely attributed to growth in data center industrial loads. Revenue totaled $807 million, outpacing the consensus estimate of $794.08 million. Following the announcement,…
-
Centene Shares Drop 10% Following Unexpected Quarterly Loss
Centene (NYSE:CNC) reported a surprise quarterly loss on Friday, citing revenue declines linked to its government-sponsored health programs, which led to a significant earnings shortfall. The health insurer’s stock fell more than 10% in premarket trading. Centene recorded a second-quarter loss of $0.16 per share, well below analyst estimates of earnings of $0.39 per share.…
-
Aon Surpasses Q2 Earnings Estimates on Robust Revenue Growth
Aon plc delivered second-quarter 2025 adjusted earnings that beat analyst forecasts, supported by solid organic revenue expansion across its divisions and enhanced operational efficiencies. The company reported adjusted earnings per share of $3.49, exceeding the consensus estimate of $3.40. Total revenue rose by 11% to $4.16 billion, just shy of the expected $4.17 billion, while…